Question Bank › Sequential re-rating

Sequential re-rating

Sequential re-rating: management describes the same offering landing bigger the second and third time around

Calls Tested
498
Answered YES
7
Hit Rate
1.4%
rare by design

Park-Ohio Holdings Corp. (PKOH) — this company's answers

NO on the Q3 2022 call 2022-11-13 B
The model's full reasoning — Q3 2022 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks: does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago? Looking at the transcript, we have statements about record sales, backlogs, etc. But we need to see if there is a specific comparison of unit size. For example, in Engineered Products, they mention "New equipment bookings in the first nine months of the year totaled $175 million compared to $148 million a year ago, an increase of 18%." That is total bookings, not necessarily average order size. They also mention "Equipment backlogs totaled $166 million at the end of September compared to $121 million at the end of last year." That is backlog, not necessarily individual order size. The question is about the size of each engagement, not total volume. Management does not explicitly say that the average order size has increased, or that new orders are larger than before. They talk about strong demand, record sales, and backlogs, but that could be due to more orders or higher prices. They do mention "increased customer pricing" but that is price increases, not larger scope. Also, they mention "business launch last year" in Assembly Components, but that is about new programs, not necessarily larger size. There is no mention of "progressively larger" deals. The only thing close is that they have record backlogs, but that doesn't indicate that each order is bigger. Thus, the answer is NO.

← Back to the full PKOH analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE — that is, does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago, so that each new instance of essentially the same business is worth more to the company than the last? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent phenomenon as a present-tense reality: the unit size of the company's own repeatable business is escalating. Any genuine expression of this counts, and the form varies widely across industries. For example — management noting that the average size of new orders, contracts, or deals has stepped up versus what the company used to sign; that its newest customers are starting at a level its early customers took years to reach, or are entering at broader scope from the outset; that where it once sold a single unit, department, site, or product, the same type of buyer now commits to many at once; that follow-on commitments from the same counterparties are arriving at multiples of the initial ones; that the projects, programs, or engagements it is now being awarded are individually larger or longer-dated than its historical norm; that initial commitments increasingly arrive as full deployments rather than as trials; or that the largest single piece of business in the company's history was just signed and management presents it as part of an upward drift in deal size rather than an isolated event. Three things should come through in management's own voice. First, A COMPARISON AGAINST THE COMPANY'S OWN RECENT PAST — management contrasts the size or scope of what it is landing now with what it was landing before for substantially the same offering, so the point is escalation of unit size, not merely more units or a good quarter. Second, ALREADY REAL AND RECURRING — the larger instances are things actually signed, ordered, awarded, or begun in the recent period, and management conveys a pattern rather than one exceptional event; a single record deal counts only if management frames it as part of an upward drift in the size of what the company is winning. Third, EARLY — management conveys, directly or plainly in substance, that this escalation is recent enough that the reported results still largely reflect the smaller-instance era, and that further instances at the new, larger size are already forming, in negotiation, or expected to keep arriving. Answer NO if management simply reports strong demand, more customers, higher revenue, or a good quarter without conveying that the individual size of what it lands has grown versus its own past. NO if the growth described comes purely from volume — more of the same-sized business — or from price increases on unchanged scope. NO if larger deals are only hoped for, targeted, sitting in a pipeline, or described as an ambition to move upmarket. NO if the only evidence is one outsized transaction that management itself treats as exceptional or non-repeating. NO if large engagements have always been the ordinary unit of this company's business and nothing about their size has changed. NO if management is chiefly describing deal sizes shrinking, scopes being cut, customers downsizing commitments, or contracts being renegotiated smaller. NO if the escalation is already mature and fully reflected in current results, with nothing further ahead. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ASO Academy Sports and Outdoors, Inc. Q1 2024 2024-06-11 C+
AKYA Akoya Biosciences, Inc. Q2 2023 2023-08-07 C+
SPT Sprout Social, Inc. Q2 2023 2023-08-04 B+
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
ASAN Asana, Inc. Q2 2022 2021-09-01 B+
OWL Blue Owl Capital Inc. Q2 2021 2021-08-10 B+

How the model reasoned

AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.

More from the question bank

Answers go deeper than the scriptFresh evidence outrunning the reported numbeSold before it existsCustomers coming back on their ownPromise already turning into factThe open question just closedAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.